| |
Centre for Policy on Ageing | |
 | |
|
Pharmacotherapy of Alzheimer's disease
— is there a need to redefine treatment success? | | Author(s) | Bengt Winblad, Henry Brodaty, Serge Gauthier |
| Journal title | International Journal of Geriatric Psychiatry, vol 16, no 7, July 2001 |
| Pages | pp 653-666 |
| Keywords | Dementia ; Drugs ; Clinical surveys ; Research Reviews. |
| Annotation | The traditional aim of Alzheimer's disease (AD) treatment in clinical trials has been to improve cognitive abilities; however, other aspects are important in assessing treatment responses. 10 physicians met to review the current criteria for assessing treatment success in AD. While cognition has been previously viewed as the primary measure of efficacy, areas such as functional abilities, behaviour, caregiver burden, quality of life and resource use all need to be assessed comprehensively to evaluate treatment effects in patients with AD, as well as their impacts on caregivers and society. Postponing or slowing decline in any of these areas may represent an important benefit and should be considered as an outcome measure in clinical trials, practice and decision-making about healthcare budgets. Some of the most frequently used outcome measures for AD are reviewed. Using expanded criteria for treatment success and clinically relevant outcome measures, data from currently available studies show that cholinesterase inhibitors produce clinically meaningful long-term benefits in multiple domains in patients with AD. (RH). |
| Accession Number | CPA-010815201 A |
| Classmark | EA: LLD: 3G: 3A:6KC |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|